Togaviridae infectious disease

This early-stage trial tests a new vaccine called PepGNP-ChikV, made from tiny synthetic particles, to see if it is safe and triggers an immune response against chikungunya virus. Forty healthy adults aged 18 to 60 will receive two doses 42 days apart. The study focuses on safety…

This Phase 3 trial will test whether giving the dengue and chikungunya vaccines at the same time is as safe and effective as giving them separately. The study involves 900 healthy adults aged 18 to 59 who have never been exposed to either virus. Researchers will measure immune re…

This study compares two common antibiotic combinations—vancomycin with piperacillin/tazobactam versus vancomycin with meropenem—to see which is less harmful to the kidneys. About 852 hospitalized adults with serious infections will be randomly assigned to one of the two combos. T…

This study tests whether a 20-session exercise program can improve muscle strength, reduce fatigue, and help with balance in people who had dengue or chikungunya in the last five years. Fifty-four adults will do supervised aerobic, strength, and breathing exercises twice a week. …

This observational study will look at 10,000 adults in intensive care units (ICUs) around the world during a single 24-hour period. Researchers want to find out how common infections and antibiotic-resistant bacteria are, how they are treated, and how patients recover. No new tre…

This research project aims to understand why older adults get more infections and why those infections can be more serious. By following 23,000 people aged 60 and older, scientists will collect health data and samples like blood and stool to study how the immune system changes wi…

This study follows 200 pregnant women in Brazil who received the chikungunya vaccine (VLA1553) during pregnancy or shortly before. Researchers will track pregnancy and infant health up to 12 weeks after birth, comparing them to a similar group of women who got routine vaccines. T…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study will follow 300 adults with severe infections in the ICU to see how levels of specialized pro-resolving mediators (SPMs)—natural molecules that help stop inflammation—change over time. Researchers will use blood samples already collected during routine care, so no extr…